Mechanical Thrombectomy of Medium Sized Vessels "M2 of MCA".

NCT ID: NCT05091320

Last Updated: 2021-10-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-01

Study Completion Date

2022-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Mechanical thrombectomy recently has revolutionized the treatment of stroke. Trials have demonstrated the superiority of mechanical thrombectomy in large vessel occlusions, such as in the intracranialinternal carotid artery and proximal, middle cerebral artery (M1), middle cerebral artery trunk (M1), have relatively high rates of revascularization and favorable clinical outcomes after MT. , However second-order branches of the middle cerebral artery (M2) occlusions (postbifurcation in the Sylvian fissure) were underrepresented or not represented in the trials. Posing a more significant technical challenge to the available endovascular devices because of the smaller size and tortuosity of these arteries and the greater likelihood of recanalization with intravenous thrombolysis, the overall risk-benefit remains uncertain.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

this study aims to:

1. compare efficacy of mechanical thrombectomy over medical treatment in occlusion of M2 division of MCA.
2. improve outcome of acute ischemic stroke.

The study will include all patients with AIS attending to emergency deparment with proven occlusion of M2 division of MCA, and deviding then into 2 groups:

Group 1 will receive medical treatment (rTPA if presented in the first 4 hours, and antiplatelet if passed time window for IVT) Group 2 will underwent mechanical thrombectomy (if accessible), and even after receiving medical treatment and not improved and comparing the outcomes of these 2 groups

c. Sample Size Calculation: Sample size was calculated using G\*power, version 3.1.9.7. Estimation based on results of previous study which reported that, median (IQR) discharge NIHSS in mechanical thrombectomy group was 2 (0-4) compared to 1 (0-2) in medical management group giving medium effect size . With a power of 80% (using one-sided t-test, effect size = 0.65 and α of 0.5) the sample needed for the study was estimated to be 60 patients (30 in each group).

Study design:

All patients are subjected to the following: -

* Enrolled patients were admitted to stroke units or intensive care units.
* Intravenous t-PA was allowed if begun within \< 4.5 hours after symptom onset.
* Thrombectomy will be performed with any FDA approved thrombectomy device by the use of local anesthesia (general anesthesia will be discouraged).

Imaging

* Patients presented with clinical picture and radiography suggestive of large vessel occlusion and who meet the proposed clinical criteria for EVT will be subjected to a comprehensive evaluation with:
* Arterial imaging of the cerebral circulation with preferably with CTA or alternatively with magnetic resonance angiography to
* Perfusion imaging with perfusion CT or with diffusion weighted imaging MRI can allow identification and quantification of the ischemic penumbra and, therefore, is useful for assessing patient eligibility for EVT in the extended time window.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke, Acute Ischemic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

case control
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mechanical thrombectomy

this arm will include all patient underwent mechanical thrombectomy, either alone or after failure of medical treatment.

Group Type ACTIVE_COMPARATOR

Mechanical thrombectomy

Intervention Type DRUG

Mechanical thrombectomy is interventional method and the first line management in large vessel occlusion in acute ischemic stroke

medical treatment

Intervention Type DRUG

medical management of patient according guide lines, either alteplase if presented in it's time window, or anti-platelet

medical managemnet

this arm will include all patients who received medical treatment only, either anti-platelet or alteplase.

Group Type ACTIVE_COMPARATOR

medical treatment

Intervention Type DRUG

medical management of patient according guide lines, either alteplase if presented in it's time window, or anti-platelet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mechanical thrombectomy

Mechanical thrombectomy is interventional method and the first line management in large vessel occlusion in acute ischemic stroke

Intervention Type DRUG

medical treatment

medical management of patient according guide lines, either alteplase if presented in it's time window, or anti-platelet

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>18 years
* Cerebral infarction in anterior circulation involving occlusion of M2 MCA, proven by CTA
* With or without IV thrombolysis
* Access to endovascular treatment within 24 hours from onset.

Exclusion Criteria

1. Proven proximal occlusion of MCA.
2. Disability prior to the stroke (mRS \>3)
3. Opposition of the patient or their family
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mahmoud Nageeb

assistant lecurer of neurology

Responsibility Role PRINCIPAL_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Neurointervintion and stroke

Identifier Type: -

Identifier Source: org_study_id